ASPIRE for TriActiv FX
This article was originally published in The Gray Sheet
Executive Summary
Kensey Nash completed enrollment for its 100-patient, 20-center ASPIRE prospective registry Nov. 7, two months ahead of schedule, the firm announced. The second-generation TriActiv FX embolic protection system for saphenous vein graft procedures received a CE mark March 7 (1"The Gray Sheet" March 21, 2005, p. 27). The firm expects to submit a 510(k) application to FDA within 90 days and could roll out the device in the first half of 2006. FDA recently approved an investigational device exemption for a feasibility study to test TriActiv FX in carotid stenting procedures (2"The Gray Sheet" Nov. 7, 2005, In Brief)...
You may also be interested in...
Kensey Nash Predicts FDA Will Approve TriActiv In Next 30 Days
U.S. clearance of Kensey Nash's TriActiv embolic protection system will not be affected by the fact that FDA has not yet approved drug-eluting stents for treating saphenous vein grafts
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.